Mercer Global Advisors
CTKB icon

Mercer Global Advisors’s Cytek Biosciences CTKB Stock Holding History

Mercer Global Advisors’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$127K Buy
29,115
+7,389
+34% +$34.9K ﹤0.01% 2963
2025
Q4 		$110K Sell
21,726
-8
-0% -$37 ﹤0.01% 2696
2025
Q3 		$75.4K Buy
+21,734
New +$81.6K ﹤0.01% 2560

Other funds holding CTKB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Mercer Global Advisors's CTKB Position: Q1 2026 in Review

Mercer Global Advisors increased its Cytek Biosciences (CTKB) stake by 34% in Q1 2026, buying an estimated $34.9K and bringing the position to 29,115 shares worth $127K. The position accounts for ﹤0.01% of the portfolio, ranked #2963.

Mercer Global Advisors first reported a position in CTKB in Q3 2025 and has held it in 3 quarters since. 165 funds tracked by Wall St. Rank hold CTKB as of Q1 2026.

  • Mercer Global Advisors held 29,115 shares of Cytek Biosciences worth $127K as of Q1 2026.
  • Mercer Global Advisors bought 7,389 Cytek Biosciences shares in Q1 2026, an estimated $34.9K.
  • Cytek Biosciences made up ﹤0.01% of Mercer Global Advisors's portfolio in Q1 2026, its #2963 holding.
  • Mercer Global Advisors first reported a position in Cytek Biosciences in Q3 2025 and has held it in 3 quarters since.
  • 165 funds tracked by Wall St. Rank held Cytek Biosciences as of Q1 2026.

Based on Mercer Global Advisors's 13F filing for Q1 2026, filed 15 May 2026.